Antibody response to COVID-19 booster vaccine in rituximab treated patients with ANCA associated vasculitis

The success of the coronavirus infectious disease 2019 (COVID-19) vaccine has been accompanied by challenges, which include suboptimal response in patients on immunosuppression. Although booster doses of the vaccine have led to an increment in number of patients (solid organ transplant recipients and patients with rheumatic disease) achieving an antibody response, a considerable proportion continue to demonstrate none. 1,2 While it is known that administration of rituximab is associated with lower response to the initial vaccine series, 3 there is a paucity of data regarding its effect with respect to booster doses.
Source: Kidney International - Category: Urology & Nephrology Authors: Tags: letters to the editor Source Type: research